Warfarin is one of the medications for which seemingly small changes in drug metabolism can have serious consequences. Prescribed to prevent dangerous blood clots in people with conditions such as atrial fibrillation, mechanical heart valves, deep-vein thrombosis, and pulmonary embolism, warfarin must be carefully adjusted so that anticoagulation is strong enough to prevent clotting without becoming strong enough to cause excessive bleeding. Marijuana complicates that balance because major cannabis compounds—including THC and CBD—can influence some of the same liver enzymes responsible for eliminating warfarin.
Evidence directly examining marijuana and warfarin is limited compared with the research available for many conventional drug interactions. There are no large randomized trials in which people taking warfarin have intentionally been assigned different doses of cannabis, and such trials would present obvious safety challenges. Nevertheless, laboratory studies, university research, pharmacological reviews, and multiple clinical case reports point in the same direction: cannabinoids can potentially increase warfarin exposure and raise the international normalized ratio, or INR. The interaction does not occur predictably in every patient, but because warfarin has a narrow therapeutic window, even an uncommon interaction deserves serious attention.
How Warfarin Works
Warfarin reduces the body’s ability to produce several vitamin K-dependent clotting factors. Rather than directly dissolving existing blood clots, it decreases the blood’s capacity to form new clots and prevents existing ones from enlarging. The strength of this anticoagulant effect is monitored using the INR, a standardized measurement derived from prothrombin time. The appropriate INR target depends on why warfarin is being prescribed, but many patients are managed within a relatively narrow range. An INR that becomes too low may leave someone vulnerable to thrombosis, while an INR that becomes excessively high increases the likelihood of bleeding.
Current U.S. prescribing information emphasizes that warfarin can cause major or fatal bleeding and that drug interactions are a central part of safe treatment. Warfarin actually consists of two mirror-image forms, or enantiomers, known as S-warfarin and R-warfarin. S-warfarin is approximately two to five times more potent as an anticoagulant and is metabolized primarily by the liver enzyme CYP2C9. R-warfarin is processed more heavily by CYP1A2 and CYP3A4. The FDA-approved labeling specifically warns that substances inhibiting CYP2C9, CYP1A2, or CYP3A4 can increase warfarin exposure and raise INR.
Why Marijuana Can Interact With Warfarin
Cannabis contains many pharmacologically active compounds, but THC, CBD, and cannabinol, or CBN, are among the cannabinoids most relevant to drug interactions. Research from Hokuriku University’s Faculty of Pharmaceutical Sciences examined THC, CBD, and CBN against CYP2C9 in human liver microsomes and recombinant enzymes. All three cannabinoids inhibited CYP2C9 activity, including the specific CYP2C9 reaction responsible for metabolizing S-warfarin. THC and CBN demonstrated particularly strong inhibition in the laboratory model, while CBD also inhibited the enzyme under several experimental conditions.
If CYP2C9 activity is reduced, the body may eliminate S-warfarin more slowly. Warfarin concentrations can then remain elevated for longer, potentially producing a higher INR and greater anticoagulant effect. A 2023 investigation of medicinal cannabis extracts similarly found that both THC and CBD inhibited enzymes involved in the metabolism of coumarin anticoagulants such as warfarin. Importantly, laboratory enzyme studies demonstrate biological plausibility rather than proving exactly how much a particular marijuana product will change INR in an individual patient. The dose, route, THC-to-CBD ratio, frequency of use, genetics, liver function, diet, and other medications can all alter the final effect.
The University of Wyoming Warfarin-Marijuana Case
One of the earliest and most striking clinical reports came from researchers at the University of Wyoming School of Pharmacy. In the 2009 report, a 56-year-old man who had taken warfarin for approximately 11 years following mechanical heart-valve replacement was admitted with an upper gastrointestinal bleed. His INR was 10.41 and his hemoglobin had fallen to 6.6 g/dL. He required fresh frozen plasma and vitamin K to reverse the excessive anticoagulation.
Only 15 days after leaving the hospital, the patient returned with persistent nosebleeding, increased bruising, and an INR of 11.55. Investigators determined that he had been smoking substantially more marijuana during this period. After counseling, he stopped cannabis use; over the following nine months he did not experience similarly severe bleeding complications. The authors classified the marijuana-warfarin interaction as probable after considering other potential explanations. A case report cannot establish how frequently this occurs, but INR values above 10 combined with gastrointestinal and nasal bleeding demonstrate why the interaction cannot be dismissed as purely theoretical.
Edible Cannabis Can Also Affect INR
Smoking is not required for an interaction. Pharmacists at the University of California San Diego’s Skaggs School of Pharmacy reported the case of a 35-year-old man whose warfarin therapy had remained remarkably stable for years at 10 milligrams per day. His INR target was approximately 2.5, with an accepted range of 2.0 to 3.0. After approximately one month of using edible cannabis while also smoking marijuana, his INR unexpectedly increased to 7.2. Investigators found no more convincing alternative explanation for the change.
The patient temporarily withheld warfarin under medical management and discontinued cannabis, after which his INR fell. The researchers considered CYP2C9 inhibition the most plausible mechanism and concluded that the interaction was probable. This case is particularly useful because it shows that the issue is not simply an effect of smoke on liver enzymes. Oral cannabinoids reach the bloodstream differently from inhaled THC, but they can still inhibit metabolic pathways and may produce prolonged cannabinoid exposure because oral THC is converted to active metabolites and absorbed more slowly.
CBD Is Not Automatically the Safer Option
Because CBD does not normally produce marijuana’s characteristic intoxication, it is sometimes assumed to be harmless alongside prescription medications. Warfarin provides a strong example of why that assumption is unsafe. Researchers from the University of Alabama at Birmingham’s CBD Program published a case involving a patient receiving stable warfarin therapy who began pharmaceutical cannabidiol as part of an epilepsy treatment program. As the CBD dose was gradually increased, the patient’s INR rose repeatedly.
Maintaining therapeutic anticoagulation ultimately required reducing the patient’s warfarin dose by approximately 30 percent. The authors concluded that INR should be monitored closely whenever cannabinoids are introduced in someone taking warfarin. The case involved high-dose pharmaceutical CBD rather than a typical low-dose retail CBD product, so the magnitude of the interaction should not automatically be applied to every CBD gummy or tincture. Still, it proves that CBD exposure can become clinically significant in a person taking warfarin.
THC Dose Changes May Matter as Much as Cannabis Use
The interaction appears capable of changing when cannabis dosage changes, even if a patient has already been using marijuana. A 2021 case report published through the American Pharmacists Association described a 67-year-old patient using medical cannabis for chronic pain who developed a supratherapeutic INR of 5.2 after increasing his THC intake. The patient did not experience bleeding, but warfarin had to be withheld temporarily until the INR returned toward the therapeutic range.
That observation has important practical implications. Someone who has used the same cannabis dose for months while maintaining a stable INR should not assume that doubling an edible dose, switching to a high-potency concentrate, adding a THC tincture, or beginning frequent cannabis use will leave warfarin unchanged. The same principle applies in the opposite direction: abruptly stopping or greatly reducing cannabis could theoretically change warfarin metabolism again. Warfarin management depends on consistency, so major changes in cannabinoid exposure deserve the same type of attention given to changes in interacting medications or dietary vitamin K intake.
The Interaction Does Not Happen in Every Patient
Not every published case shows a dramatic increase in INR. Researchers from the Philadelphia College of Pharmacy and the Corporal Michael J. Crescenz VA Medical Center described an 85-year-old patient taking warfarin who began an oromucosal medical cannabis preparation containing both THC and CBD. Despite daily cannabinoid exposure, the patient’s INR remained relatively stable for almost a year. The doses involved were quite low—roughly 0.3 milligrams of THC and 5.3 milligrams of CBD daily, with a small additional as-needed dose.
The investigators suggested that interaction risk may depend heavily on cannabis dose and route of administration. This case is valuable because it prevents the evidence from being interpreted too broadly. Cannabis does not inevitably cause dangerous anticoagulation in every warfarin user. Instead, the available evidence suggests a dose-dependent and highly individual interaction. Unfortunately, no reliable cannabis dose has been established below which an interaction can be considered impossible. Product labeling also varies considerably, meaning two products described as “CBD oil” or “THC gummies” may deliver dramatically different cannabinoid exposure.
What Broader Reviews Have Concluded
A review conducted by researchers associated with Aarhus University Hospital, the University of Southern Denmark, and other Danish medical institutions examined the available warfarin-cannabis literature. After screening 85 articles, researchers found only a small number of directly relevant studies: laboratory CYP2C9 research and several case reports. Despite the limited evidence base, the available findings consistently pointed toward cannabinoids increasing INR. Their review included the patient whose INR exceeded 10 during increased marijuana use and the CBD patient whose warfarin dose eventually required a 30 percent reduction.
More recent pharmacokinetic reviews have reached a similar conclusion. Among anticoagulants, warfarin stands out as the medication for which cannabinoid interaction evidence is most developed. CBD can inhibit CYP2C9 and CYP3A4, while THC can inhibit CYP2C9, creating plausible mechanisms for increased warfarin exposure. The absence of large clinical trials means researchers cannot calculate a precise percentage increase in INR for a given amount of THC or CBD, but the combination of enzyme studies and repeated clinical reports justifies careful monitoring.
Bleeding Is the Major Concern
An elevated INR does not automatically mean that bleeding will occur, but the likelihood of bleeding rises as anticoagulation becomes excessive. Warning signs can include unusually easy bruising, prolonged bleeding from small cuts, frequent or persistent nosebleeds, bleeding gums, unusually heavy menstrual bleeding, pink or red urine, black or bloody stools, vomiting blood, or coughing up blood. Severe headache, sudden weakness, confusion, loss of coordination, fainting, or neurological changes can potentially indicate internal bleeding and require urgent medical evaluation.
Warfarin already carries an FDA boxed warning for major or fatal bleeding, independent of cannabis. Age, previous bleeding, uncontrolled hypertension, kidney or liver disease, certain genetic variants, other anticoagulant or antiplatelet medications, and drugs such as NSAIDs can further increase risk. Cannabis therefore may represent only one component of a much larger interaction profile. Someone taking warfarin should never independently skip doses, lower the dose, or take extra vitamin K simply because cannabis has been consumed; excessive correction can shift the problem in the opposite direction and increase the risk of dangerous clotting.
INR Monitoring Becomes Especially Important
Warfarin differs from many medications because clinicians have a readily measurable way to detect changes in its effect. INR testing can reveal increasing anticoagulation before obvious bleeding develops. When someone taking warfarin begins smoking marijuana, starts using CBD, substantially changes the strength or amount of a cannabis product, or stops regular cannabis use, closer INR monitoring may allow the healthcare team to identify a change before it becomes dangerous.
The same information should be shared with the anticoagulation clinic, physician, and pharmacist. Describing cannabis use simply as “occasional marijuana” may not be sufficient. Clinically useful details include whether the product contains THC, CBD, or both; whether it is smoked, vaporized, eaten, or taken as an oil; approximate cannabinoid dosage; how frequently it is used; and whether the pattern recently changed. A 5-milligram THC edible taken once a month is pharmacologically very different from high-dose CBD oil consumed twice a day or concentrated THC used throughout the day.
Genetics Can Add Another Layer
Individual responses to warfarin already vary substantially before cannabis is added. Current warfarin labeling identifies CYP2C9 genetic variants as important contributors to warfarin dose requirements. People carrying reduced-function variants such as CYP2C92 or CYP2C93 clear S-warfarin more slowly and may therefore require lower doses. Research has associated these variants with greater susceptibility to excessive anticoagulation and bleeding during warfarin therapy.
In theory, cannabinoid inhibition of CYP2C9 could be more consequential in someone whose metabolic capacity is already reduced, although direct clinical research specifically examining cannabis-warfarin interactions by CYP2C9 genotype is lacking. This is one reason anecdotes from individual cannabis users are unreliable guides. One person may combine marijuana and warfarin for years without obvious difficulty, while another may experience a substantial INR increase after changing THC or CBD exposure.
Final Thoughts on Marijuana and Warfarin
Among potential cannabis-drug interactions, marijuana and warfarin deserve particular attention because the biological mechanism is plausible and the clinical consequences can be serious. Warfarin’s most potent S-enantiomer depends heavily on CYP2C9 metabolism, and laboratory research shows that THC, CBD, and CBN can inhibit that enzyme. Published cases have documented INR values of 5.2, 7.2, and above 10 following increased cannabinoid exposure, including episodes associated with serious bleeding. Pharmaceutical CBD has also produced rising INR values that ultimately required a substantial reduction in warfarin dosage.
At the same time, the evidence does not show that every cannabis user taking warfarin will experience an interaction. At least one published medical cannabis case involving low cannabinoid doses showed minimal INR change, suggesting that dose, formulation, route, individual metabolism, and genetics all matter. The safest conclusion is therefore not that marijuana and warfarin are universally incompatible, but that combining them requires medical awareness and appropriate INR surveillance. People taking warfarin should inform their anticoagulation team before beginning, stopping, or substantially changing THC or CBD use, and they should seek prompt medical attention when unexplained bleeding or symptoms of serious internal bleeding develop.
